---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-001684"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2022-02-23T23:59:59+00:00"
generated_at: "2026-06-27T05:26:07.093139+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences: KSI-301 fails primary endpoint in wet AMD Phase 2b/3 trial

## Summary
- Primary endpoint not met: KSI-301 failed to show non-inferior visual acuity gains vs aflibercept in wet AMD.
- Cash and cash equivalents at Dec 31, 2021 were approximately $731.5M.
- Pre-specified secondary analysis: 59% of KSI-301 patients achieved 5-month dosing with comparable visual acuity and anatomic improvements.
- Safety: KSI-301 generally safe; intraocular inflammation in 3.2% vs 0% for aflibercept; all resolved.
- Trial randomized 559 participants, ~80% in US; flexible long-interval regimen for KSI-301 vs fixed 2-month for aflibercept.

## SEC filing metadata
- accession: 0000950170-22-001684
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2022-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017022001684/0000950170-22-001684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017022001684/kod-20220223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-001684
- JSON: https://secwatch.observer/filing/0000950170-22-001684.json
- Plain text: https://secwatch.observer/filing/0000950170-22-001684.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.